Drug intelligence / Profile preview

cyclophosphamide + prednisone + rituximab

Development stage
Unknown
Lead developer
Genentech
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration
Intravenous, Oral, Subcutaneous
01

Overview

This is a combination regimen consisting of three drugs: - **Cyclophosphamide** (an alkylating agent/chemotherapy drug that interferes with DNA replication and cell division, leading to cancer cell death) - **Prednisone** (a synthetic glucocorticoid corticosteroid that suppresses inflammation and immune responses, also used as part of cancer regimens for its cytotoxic effects on certain lymphoid cells) - **Rituximab** (a monoclonal antibody targeting CD20 on B lymphocytes, leading to their destruction via immune-mediated mechanisms) This combination is used in the treatment of various B-cell non-Hodgkin lymphomas. Each component has a distinct mechanism of action, contributing synergistically to anti-tumor activity. The regimen may be used alone or as part of larger multi-drug protocols such as R-CVP or R-CHOP[1][2][3].

02

Targets

DNAGR (Glucocorticoid receptor)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on cyclophosphamide + prednisone + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + prednisone + rituximab.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call